RTP Mobile Logo
Submitted by web@researchtop... on Wed, 06/12/2019 - 15:37

 

Module 1: Genomic Testing and Management of Primary Ovarian Cancer

Track 1: Molecular profiling for patients with newly diagnosed ovarian cancer
Track 2: Therapeutic approach for patients with newly diagnosed Stage III ovarian cancer and germline BRCA mutations
Track 3: SOLO-1: A Phase III trial investigating olaparib as maintenance therapy for patients with newly diagnosed, advanced ovarian cancer and BRCA mutations who experienced a response to first-line platinum-based chemotherapy
Track 4: Perspective on the optimal time to start maintenance therapy with PARP inhibitors for patients with newly diagnosed ovarian cancer
Track 5: Case (Dr Godoy): A woman in her mid-60s with Stage IIIC serous fallopian tube carcinoma and a germline BRCA1 mutation begins maintenance olaparib 1 year after treatment with cytoreduction and chemotherapy
Track 6: Case (Dr Brosnan): A woman in her late 60s with Stage IIIC high-grade serous ovarian cancer is found to have a BRCA1 Q780E mutation of unknown significance

Module 2: Role of PARP Inhibition in the Management of Relapsed Ovarian Cancer

Track 7: Selection of therapy for patients with relapsed ovarian cancer
Track 8: Choice of PARP inhibitor and dosing considerations with niraparib
Track 9: Case (Dr Polkinghorn): A woman in her mid-60s with recurrent Stage IIIC papillary serous ovarian cancer maintains a complete response after treatment with carboplatin/paclitaxel/bevacizumab followed by maintenance bevacizumab
Track 10: Case (Dr Mallen): A woman in her late 50s with Stage IIIC high-grade serous ovarian cancer and a germline BRCA1 mutation presents with pleural effusion 6 months after debulking surgery and carboplatin/paclitaxel
Track 11: Case (Dr Godoy): A woman in her early 80s with germline BRCA mutation-negative status and recurrent peritoneal serous adenocarcinoma receives niraparib 6 months after treatment with carboplatin/paclitaxel

Module 3: Prevention, Recognition and Management of PARP Inhibitor-Associated Side Effects

Track 12: Case (Dr Brosnan): A woman in her mid-50s with recurrent high-grade serous ovarian cancer and a germline BRCA1 mutation experiences nausea, vomiting and dyspepsia after treatment with olaparib
Track 13: Effect of PARP inhibitors on circadian rhythms
Track 14: Case (Dr Brosnan): A woman in her mid-60s with multiply recurrent ovarian cancer experiences a doubling of her serum creatinine level within weeks of initiating rucaparib monotherapy

Module 4: Investigational Application of Approved PARP Inhibitors; Other PARP Inhibitors in Clinical Development

Track 15: Case (Dr Godoy): A woman in her mid-50s with germline BRCA mutation-negative status presents with an isolated recurrence in the brain 2 years after treatment for Stage IV mixed clear cell and serous ovarian cancer
Track 16: Emerging data with PARP inhibitors combined with anti-angiogenic agents and immune checkpoint inhibitors
 
FACULTY
 
Robert L Coleman, MD
Professor and Executive Director
Cancer Network Research
Ann Rife Cox Chair in Gynecology
Department of Gynecologic Oncology
and Reproductive Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas
 
Professor Jonathan A Ledermann
Professor of Medical Oncology
Clinical Director
University College London Cancer Institute
Director
Cancer Research UK and UCL Cancer Trials Centre
London, United Kingdom
 
Stephanie Lheureux, MD, PhD
Staff
Medical Oncology-Gynecology and Drug Development Program
Gynecology Site Lead at
Princess Margaret Cancer Centre
Assistant Professor, University of Toronto
Toronto, Canada

 
Kathleen Moore, MD
Jim and Christy Everest Endowed
Chair in Cancer Research
Associate Director
Clinical Research
Director
Oklahoma TSET Phase I Program
Stephenson Cancer Center
Associate Professor
Section of Gynecologic Oncology
Director, Gynecologic Oncology Fellowship
Department of Obstetrics and Gynecology
University of Oklahoma
Health Sciences Center
Oklahoma City, Oklahoma
 
MODERATOR
 
Neil Love, MD
Research To Practice
Miami, Florida